App-Quantinova.ai

Venous thromboembolism and race: A systematic review and meta‐analysis

K. Butterworth - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Cost savings following implementation of new VWF testing algorithm

P. Player - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Congenital bile acid synthesis defect

N/A

Can long acting factors go a long way; a real‐life single centre retrospective study of Haemophilia B patients who have switched to extended half‐life factor IX

A. Rampotas - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Hemophilia

Alprolix Intravenous

Desmopressin for reversal of Antiplatelet drugs in Stroke due to Haemorrhage (DASH): rationale and design of a phase II double blind randomised controlled trial

M. Desborough - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Stroke

rFVIIa

Apixaban Length‐Of‐Stay Pulmonary Embolism study ‐ Hospital Admissions (ALPHA‐PE)

R. Alikhan - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pulmonary embolism

apixaban

Retrospective Audit Of The Use Of Intravenous Unfractionated Heparin Within A Major Tertiary Hospital

R. Witherall - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Thrombocytopenia

Heparin

Apixaban plasma levels in obese patients

V. Ware - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Arrhythmia

apixaban

Serious bleeds as a consequence of direct oral anticoagulant dosing errors and the development of the DOAC hospital checklist as a patient safety initiative

J. Mainwaring - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Arrhythmia

Prothrombin complex

Extensive screening for occult malignancy in all unprovoked venous thromboembolism above 40 years old: Are we overdoing it?

C.L. Neoh - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Methadone hydrochloride

Glanzmann Thrombocythaemia with very mild bleeding phenotype

M. Tahhan - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Glanzmann thrombasthenia

Fibrinogen (IV)

Poor communication between clinicians and laboratory staff puts haemopoietic stem cell transplant recipients at risk of transfusion error – data from the Serious Hazards of Transfusion (SHOT) haemovigilance scheme

S. Stirling - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Cytomegalovirus infection

N/A

Errors in providing D or K matched blood components to women of child bearing potential — 2013‐2017 data from SHOT and MHRA, UK

H. Mistry - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Episodic ataxia 2

N/A

A Therapeutic Approach to Platelet Transfusions in BEAM and HDM Autologous Bone Marrow Transplantation

K. Nwankiti - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Sepsis

Melphalan

Is routine Group and Save required in Primary Arthroplasty? A retrospective data collection leading to development of new local guidelines

A. Sansome - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Preliminary results from a national study of use of granulocyte transfusions: a year of ‘ProGrES’

S. Morton - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Acute myelocytic leukemia

N/A

Delayed presentation of Anti‐Rh17 alloantibody due to immunosuppression from chemotherapy and implications for ongoing treatment in a patient with T‐cell Acute Lymphoblastic Leukaemia

R. Mullally - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

T-cell acute lymphoblastic leukemia

Erythropoietin

Screening test for prion diseases: a novel approach using aptamers and tunable resistive pulse sensing

M. Healey - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Prion diseases

Intratect

A clinical decision support system allows real‐time monitoring of compliance to hospital transfusion guidelines and immediate education regarding inappropriate inpatient transfusions

A. King - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Transfusion practice in patients with autoimmune haemolytic anaemia: lessons from an English national survey

M. Horan - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Autoimmune hemolytic anemia

Prednisolone

Avoidable transfusion due to inadequate investigation of anaemia in an acute care setting

C. Prodger - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Anemia

N/A

Filters

45280 Abstracts